Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 11, 2016

View Archived Issues

Prothena reports phase Ib results for PRX-002 in Parkinson's disease

FDA removes partial clinical hold on NY-ESO SPEAR study

Retrophin reaches SPA agreement with FDA for phase III trial of RE-024 for PKAN

Galectin Therapeutics looking for potential strategic partnership for GR-MD-02

Selecta Biosciences gets worldwide rights to candidates generated through Sanofi collaboration

FDA approves Opdivo for head and neck cancer

Blisibimod CHABLIS-SC1 phase III study does not achieve primary endpoint

FDA approves Vemlidy to treat chronic HBV infection

Assembly Biosciences starts phase Ia/Ib trial of ABI-H0731

FDA grants BTD to Seattle Genetics' brentuximab vedotin

Omeros reports nonhuman primate data for MASP-3 inhibitor OMS-906

NAALADL2 identified as a drug target for prostate cancer

Celsion reports positive data for OVATION phase Ib trial

Capricor expands CAP-1002 clinical development program in DMD

RedHill Biopharma concludes type B meeting with FDA for RBH-105 phase III program

TaiMed Biologics notifies Theratechnologies of preliminary results for phase III trial of ibalizumab

VRC-01 only slightly delays HIV rebound in clinical studies

Aptinyx wins USD 2.85 million in research grants

Bristol-Myers Squibb licenses rights to Nitto Denko's siRNA molecules

Jiangsu Hansoh Pharmaceutical patents FXR agonists

Chinese researchers report CDK/cyclin inhibitors for cancer

BGI-Shenzhen develops of calcium channel blockers

Inhibikase Therapeutics describes tyrosine kinase inhibitors

Synaptic biomarkers of cognitive decline identified in patients with dementia

Genmab to test daratumumab in combination with carfilzomib and dexamethasone in MM patients

Glucagon/thyroid hormone conjugate improves experimental metabolic conditions

Lilly's Lartruvo gets conditional approval in Europe for advanced soft tissue sarcoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...